{"authors": [["Zhao", "Yun", "Y", "Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM, Marseille, France."], ["Arce-Gorvel", "Vilma", "V", "Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM, Marseille, France."], ["Conde-\u00c1lvarez", "Raquel", "R", "Instituto de Salud Tropical, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Departamento de Microbiolog\u00eda y Parasitolog\u00eda, Universidad de Navarra, Pamplona, Spain."], ["Moriyon", "Ignacio", "I", "Instituto de Salud Tropical, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Departamento de Microbiolog\u00eda y Parasitolog\u00eda, Universidad de Navarra, Pamplona, Spain."], ["Gorvel", "Jean-Pierre", "JP", "Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM, Marseille, France. Electronic address: gorvel@ciml.univ-mrs.fr."]], "date": "2017-12-09", "id": "29233768", "text": "Vaccines are one of the most important methods for preventing infectious disease. Structural modification of lipopolysaccharide (LPS) provides a strategy for the development of live attenuated vaccines, either by altering the immunogenicity or by attenuating virulence of the bacteria. This review summarizes various approaches that utilize LPS mutants as whole-cell vaccines.", "doi": "10.1016/j.micinf.2017.11.006", "title": "Vaccine development targeting lipopolysaccharide structure modification.", "journal": ["Microbes and infection", "Microbes Infect."]}